Transverse myelopathy is an uncommon complication of systemic lupus erythematosus (SLE). Three patients with SLE are reported who developed transverse myelopathy, including the neuropathological findings in one patient on whom necropsy was performed. Paraparesis was present in all three cases, but definite sensory changes were present in only one patient. In two patients, the CSF findings were remarkable for elevated protein and depressed glucose concentrations. Two years later, she developed fever, flank pain and malaise, and steroids were increased to 20 mg daily. She also developed progressive gait difficulty over the next three weeks and experienced three generalised seizures. She had no urinary symptoms but bowel movements were decreased.
Accepted 20 November 1991 Although CNS February 1983 . Initial serological studies for SLE were negative, and she was given a diagnosis of seronegative SLE. The rash responded to prednisone, 30 mg four times a day. Subsequently she was found to have a hightitre speckled ANA and antibody to SS-A and RNP. She was treated with hydroxychloroquine for three months, and steroids were tapered to a low maintenance dose eight months after onset of symptoms.
Two years later, she developed fever, flank pain and malaise, and steroids were increased to 20 mg daily. She also developed progressive gait difficulty over the next three weeks and experienced three generalised seizures. She had no urinary symptoms but bowel movements were decreased.
Neurological examination revealed moderate lethargy, poor short-term memory, normal cranial nerve examination, full strength in the arms without pronator drift but 2/5 strength diffusely in both legs. Cerebellar and sensory examination were normal. She was treated with phenytoin and phenobarbital. CT head scan showed moderate cerebral atrophy. Myelographic examination of the entire spinal cord was normal. The lumbar puncture revealed clear, colourless fluid, with 0 RBC, 0 WBC, glucose 79 mg% ( A lumbar puncture showed one red blood cell, seven white blood cells, glucose 41 mg% (no simultaneous serum glucose) and protein 248 mg%. CSF gram stain showed no organisms, and CSF culture and AFB stain were negative. MRI of the brain and entire spinal cord revealed significant cerebral atrophy but no other abnormalities.
The patient was treated with 60 mg daily of prednisone, but her confusion and leg weakness continued to worsen. She was given methylprednisolone 250 mg intravenous four times a day for three days without improvement. Visual and brainstem auditory evoked potentials were normal. Upper extremity somatosensory evoked potentials were normal while lower extremity somatosensory evoked potentials were abnormal bilaterally. A repeat lumbar puncture revealed clear, colourless fluid, with 2 RBC, 1 WBC, glucose 65 mg% (simultaneous serum glucose 142 mg%) and protein 41 mg%. The CSF/serum IgG/albumin index was 2-91 (normal range 0-34-088) and oligoclonal bands were noted in the CSF but not in the serum.
The patient had a series of 11 plasma exchange procedures over the course of the next four weeks, supplemented by an infusion of 0-75 grams of cyclophosphamide at one week. At the time of discharge three weeks after beginning plasma exchange therapy, significant improvement in the patient's encephalopathy was noted, with moderate improvement in leg strength and urinary bladder function. At the time of discharge she was able to walk with the aid of a walker.
The patient subsequently had another pulse infusion of 0 7 grams of cyclophosphamide and a single plasma exchange procedure one month after discharge. She was maintained on 60 mg prednisone daily. Six months after the onset of leg weakness, she was able to walk without a walker, could climb stairs with assistance and her bladder function had returned to normal. The most common type of pathological change reported in cases of SLE-related myelopathy is peripheral white-matter degeneration, often at multiple spinal cord levels. We have termed this characteristic pattern of spinal cord degeneration "subpial leukomyelopathy" because of its peripheral location and its primary involvement of white matter. These lesions show ballooning of myelin sheaths and axonal degeneration similar to that seen in our first case. Spinal-cord tract degeneration is not seen in these cases. As opposed to the extensive spinal cord destruction at a specific cord level in the type I category, the extent of the spinal cord degeneration at any one level in subpial leukomyelopathy may appear relatively insignificant. The fact that the lesions result in the clinical presentation of paraparesis or quadriparesis and significant sensory abnormalities is apparently due to a summation effect.
Previously reported cases of subpial leukomyelopathy are outlined in the table. Vacuolar changes were reported at all spinal cord levels in a number of these cases, although in Fisher's patient the changes were primarily at the thoracic and lumbar levels.'4 Andrews et al 6 did not describe the characteristic peripheral distribution of vacuolar changes but their case cases, but such a factor has never been identified.
Similar vacuolar changes have been described in AIDS-related myelopathy.
Petito"8 described these changes in 29% of consecutive necropsy cases of AIDS. The vacuolar degeneration was more prominent in patients with severe myelopathy. The changes were reported to be distributed throughout the spinal cord white matter, but were more prominent in the lateral columns. Like the changes seen in SLE, these abnormalities were not confined to specific anatomical tracts. As in the SLE cases, the vacuoles were surrounded by a thinned myelin sheath, suggesting that they were formed by intramyelin swelling. Similar findings have subsequently been described by other investigators."9 None of the patients in our series were known to have been exposed to any of the risk factors for AIDS, and neither of the two surviving patients has subsequently developed AIDS-like symptoms.
The peripheral distribution of the white matter degeneration in the spinal cord is similar to that described by Bunge and Settlage20 following CSF barbotage in cats. A similar peripheral pattern of degeneration in spinal cord, brainstem and optic tracts was reported by Friede and Roessman2' in a patient who had repeated lumbar punctures for a CSF leak following transsphenoidal hypohysectomy. Winkelman22 also reported peripheral spongy degeneration of the spinal cord following accidental intrathecal injection of detergent solutions during administration of spinal anaesthesia.
The possibility that these lesions are secondary to ischaemia must also be considered. Nakano 5 reported fibrinoid necrosis and severe intimal thickening in arterioles surrounding the spinal leukomyelopathy. Similar vascular changes were not found in our case or the other previously reported cases and the subpial location of the changes is not the typical location of spinal cord infarcts. Thus there is little support for the hypothesis that these lesions are related to ischaemia.
In summary, lupus myelopathy may present with a variety of signs and symptoms, which may initially lead to misdiagnosis. Although paraparesis appears to be a constant feature, there is great variability regarding sensory disturbance and changes in the reflexes. There is also great variability in the CSF findings. Pathological findings similar to those seen in our first case have been previously described, and may be characteristic of lupus myelitis, although not pathognomonic of it. Unfortunately, at present, the pathogenesis of these findings is poorly understood.
